Johnson & Johnson (JNJ) Tops Q1 EPS by 7c, Revenue Slightly Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St ends mixed as oil takes a pause
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Johnson & Johnson Reports Q1 2024 Results
April 16, 2024 6:20 AM EDT2024 First-Quarter reported sales growth of 2.3% to $21.4 Billion with operational growth of 3.9%* and adjusted operational growth of 4.0%*
Adjusted operational growth excluding COVID-19 Vaccine of 7.7%*
2024 First-Quarter Earnings per share (EPS) increased to $2.20 and adjusted EPS increased to $2.71 or 12.4%*
Company increasing the midpoint for Full-Year 2024 operational sales5 and adjusted operational EPS guidance
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2024. Johnson & Johnsons solid... More
